Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$34 Mln
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-249.30 Mln
EBITDA
$-256.16 Mln
Net Profit
$-175.57 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Akili Inc (AKLI)
| -11.29 | 2.71 | 55.01 | -61.08 | -- | -- | -- |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
2023
|
|
|---|---|
|
Akili Inc (AKLI)
| -56.52 |
|
BSE Sensex
| 18.74 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications,... including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp. Read more
Co-Founder & Chairman
Dr. Walter Edward Martucci II, Ph.D.
Co-Founder & Chairman
Dr. Walter Edward Martucci II, Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Akili Inc (AKLI) is $0.43 (NASDAQ) as of 02-Jul-2024 09:30 EDT. Akili Inc (AKLI) has given a return of -61.08% in the last 1 years.
Akili Inc (AKLI) has a market capitalisation of $ 34 Mln as on 16-Jul-2024. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Akili Inc (AKLI) and enter the required number of quantities and click on buy to purchase the shares of Akili Inc (AKLI).
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.
The CEO & director of Dr. Walter Edward Martucci II, Ph.D.. is Akili Inc (AKLI), and CFO & Sr. VP is Dr. Walter Edward Martucci II, Ph.D..
There is no promoter pledging in Akili Inc (AKLI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Akili Inc (AKLI) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Akili Inc (AKLI) was $-12 Mln.
